<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976845</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00025204</org_study_id>
    <nct_id>NCT01976845</nct_id>
  </id_info>
  <brief_title>Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Propofol or Midazolam Versus Placebo for Preoperative Medication in Patients Undergoing Elective Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is:&#xD;
&#xD;
      To evaluate the sedative (reduces irritability or agitation), anxiolytic (reduces anxiety),&#xD;
      and amnesic (produces temporary lack of recall) effects of propofol or midazolam when&#xD;
      administered for preoperative medication (before administration of drugs that will put&#xD;
      patient to sleep) in comparison to placebo. This study is to test whether the use of the&#xD;
      pre-anesthesia medication measurably reduces anxiety in comparison to receiving no&#xD;
      pre-anesthesia medication prior to orthopedic procedures.&#xD;
&#xD;
      To assess the effect of propofol in comparison to placebo and midazolam on the ability to&#xD;
      recall (memory of):&#xD;
&#xD;
        -  when the doctor places the mask on patient's face prior to going to sleep&#xD;
&#xD;
        -  recall of 2 pictures&#xD;
&#xD;
        -  on your satisfaction with the anesthesia as well as postoperative side effects in&#xD;
           post-anesthesia care unit (PACU) e.g., nausea ,vomiting and sedation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of anxiolytic premedication in the ambulatory surgical population is frequently&#xD;
      debated. Anesthesiologists may consider the administration of anxiety-reducing drugs&#xD;
      unnecessary when anxiety levels are low in outpatients presenting for minor surgery. However,&#xD;
      the previous study reports that up to 80% of outpatients expressed a preference for a&#xD;
      combination of anxiety-reducing and hypnotic premedication before surgery (1-4). In addition&#xD;
      to anxiolysis, goals of anxiolytic premedication include sedation, amnesia, improved patient&#xD;
      cooperation, and/or improved patient satisfaction. Intravenous (IV) midazolam is the most&#xD;
      commonly used premedicant in the ambulatory setting due to its rapid onset, and short&#xD;
      half-life (2,3,5), but its residual effects in the immediate postoperative period may&#xD;
      contribute to postoperative sedation, as well as to delayed recovery and discharge-readiness&#xD;
      after brief outpatient surgery. Furthermore, White et al. (6) noted that the slope of the&#xD;
      dose-response curve for sedation was much steeper with midazolam compared with diazepam,&#xD;
      which suggests that midazolam may possess a smaller margin of safety and greater need for&#xD;
      careful titration to achieve the desired clinical end-point without untoward side effects.&#xD;
&#xD;
      Propofol has become the IV (intravenous) anesthetic of choice for ambulatory anesthesia&#xD;
      because of its excellent recovery profile (7). Clinical experience with propofol in the&#xD;
      ambulatory setting suggests that its use is associated with less residual sedation and lower&#xD;
      incidence of postoperative nausea and vomiting (PONV) (8). However, there are some&#xD;
      undesirable side effects associated with propofol including pain on injection, cardiovascular&#xD;
      and respiratory depression, and occasional excitement on emergence from anesthesia (9).&#xD;
      Practically, small doses of propofol (10-20 mg IV) have been used as an anxiolytic/sedative&#xD;
      medication.&#xD;
&#xD;
      To date, there is only one study that has evaluated propofol versus midazolam versus placebo&#xD;
      as premedication (10). In this study, the authors stated that propofol (0.4 mg/kg IV) had&#xD;
      anxiolytic effects comparable in magnitude and duration to midazolam (0.04 mg/kg IV) with&#xD;
      less memory impairment, respiratory depression and dizziness. However, they did not assess&#xD;
      the efficacy of propofol and midazolam as a premedication on the recovery profiles and&#xD;
      patient's satisfaction in their study. Compared to placebo and propofol, midazolam was&#xD;
      associated with more frequent respiratory depression and significant impairment of&#xD;
      anterograde explicit memory. Both propofol and midazolam helped relieve anxiety and lowered&#xD;
      blood pressure (compared to baseline) but both were associated with greater dizziness scores&#xD;
      (P&lt;0.001, compared to placebo).&#xD;
&#xD;
      They concluded that Propofol had an anxiolytic effect comparable in magnitude and duration to&#xD;
      that of midazolam with less memory impairment, respiratory depression and dizziness.&#xD;
&#xD;
      Propofol appears to be an economical, effective and safe alternative to midazolam for&#xD;
      treating pre-anesthesia anxiety, and especially to be used for induction of anesthesia (10).&#xD;
      (This sentence is not clear).&#xD;
&#xD;
      Therefore, we designed this randomized, double-blind, and placebo-controlled study to&#xD;
      evaluate propofol as a premedication and to see if it:&#xD;
&#xD;
        -  produces comparable anxiolytic effects to midazolam when compared to placebo, but with&#xD;
           less memory impairment&#xD;
&#xD;
        -  facilitates early recovery profile&#xD;
&#xD;
        -  improves patient's satisfaction with the induction and early recovery from anesthesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on the Verbal Rating Scale For Anxiety</measure>
    <time_frame>one day</time_frame>
    <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely nervous)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores on the Verbal Rating Scale For Sleepiness (Sedation)</measure>
    <time_frame>one day</time_frame>
    <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely sleepiness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Produces Amnesia(Memory Recall)</measure>
    <time_frame>one day</time_frame>
    <description>Ability to recall (memory of):&#xD;
â€¢recall of 2 pictures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Elective Orthopedic Surgery</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol 20 mg IV (2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 2 mg IV (2 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 2 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>VERSED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline 2 ml IV, in the pre-op area as a premedication</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness and ability to sign an informed consent document&#xD;
&#xD;
          -  No allergies to midazolam or propofol&#xD;
&#xD;
          -  18 - 70 years of age&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) Class I-III adults of either sex&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known allergy, hypersensitivity or contraindications to midazolam,&#xD;
             propofol, anesthetic or analgesic medications&#xD;
&#xD;
          -  Patients with clinically-significant medical conditions, such as brain, heart, kidney,&#xD;
             endocrine, or liver diseases&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subjects with a history of alcohol or drug abuse within the past 3 months&#xD;
&#xD;
          -  Patients chronically using sedative, anxiolytic drugs prior to the surgery&#xD;
&#xD;
          -  Morbid obesity (BMI &gt;40 kg/m2)&#xD;
&#xD;
          -  Patients who are agitated or confused prior to receiving the drug ( verbal rating&#xD;
             scale [VRS] greater then 6)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald H Wender, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Ronald Wender</investigator_full_name>
    <investigator_title>Chairman, Department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>propofol</keyword>
  <keyword>midazolam</keyword>
  <keyword>sedative</keyword>
  <keyword>anxiolytic</keyword>
  <keyword>amnesic</keyword>
  <keyword>recall</keyword>
  <keyword>Memory</keyword>
  <keyword>Perioperative outcomes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prior to the day of surgery, potential study patients received a packet of materials (initial patient contact letter, a HIPAA information sheet, and the IRB approved informed consent form) from their surgeon. Patients who were interested in participating in the study were asked to bring the materials to the hospital on the day of surgery.</recruitment_details>
      <pre_assignment_details>Randomization assignment was generated with a 1:1:1 allocation ratio using a computer software program.&#xD;
The randomization number specifying the study medication was placed in sealed envelope and given to a non-participating anesthesiologist on the day of the scheduled procedure after completing the patient's preoperative assessment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Propofol</title>
          <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="P3">
          <title>Saline</title>
          <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol</title>
          <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="B3">
          <title>Saline</title>
          <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="13"/>
                    <measurement group_id="B2" value="51" spread="15"/>
                    <measurement group_id="B3" value="49" spread="14"/>
                    <measurement group_id="B4" value="51" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg^m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="5"/>
                    <measurement group_id="B2" value="28" spread="6"/>
                    <measurement group_id="B3" value="28" spread="5"/>
                    <measurement group_id="B4" value="28" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scores on the Verbal Rating Scale For Anxiety</title>
        <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely nervous)</description>
        <time_frame>one day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
          </group>
        </group_list>
        <measure>
          <title>Scores on the Verbal Rating Scale For Anxiety</title>
          <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely nervous)</description>
          <units>Scores on a Scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.8"/>
                    <measurement group_id="O2" value="2.3" spread="2.1"/>
                    <measurement group_id="O3" value="2.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scores on the Verbal Rating Scale For Sleepiness (Sedation)</title>
        <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely sleepiness)</description>
        <time_frame>one day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
          </group>
        </group_list>
        <measure>
          <title>Scores on the Verbal Rating Scale For Sleepiness (Sedation)</title>
          <description>Using the verbal rating scale (VRS) for anxiety (0= none to 10 = extremely sleepiness)</description>
          <units>Scores on a Scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.5"/>
                    <measurement group_id="O2" value="5.2" spread="2.3"/>
                    <measurement group_id="O3" value="2.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Produces Amnesia(Memory Recall)</title>
        <description>Ability to recall (memory of):&#xD;
â€¢recall of 2 pictures</description>
        <time_frame>one day</time_frame>
        <population>Subjects who recall the picture</population>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
          </group>
        </group_list>
        <measure>
          <title>Produces Amnesia(Memory Recall)</title>
          <description>Ability to recall (memory of):&#xD;
â€¢recall of 2 pictures</description>
          <population>Subjects who recall the picture</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 hours</time_frame>
      <desc>The study lasted the day of the anesthesia procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Propofol</title>
          <description>Propofol 20 mg IV (2 ml)&#xD;
Propofol: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>Midazolam 2 mg IV (2 ml)&#xD;
Midazolam: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication</description>
        </group>
        <group group_id="E3">
          <title>Saline</title>
          <description>Saline 2 ml&#xD;
Saline: Saline 2 ml IV, in the pre-op area as a premedication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ronald H Wender</name_or_title>
      <organization>Department of Anesthesiology at Cedars-Sinai Medical Center in Los Angeles</organization>
      <phone>3104231682</phone>
      <email>ronald.wender@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

